Real-world study fills gaps left by clinical trials of checkpoint inhibitors.
ONCOLOGY
Fully funded by 
Content independently selected
-
NSCLC: ECOG status predicts ICI outcomes in elderly patients -
Recurrence common in LA-NSCLC after trimodality therapy Local treatment for recurrence significantly improved survival.
-
Surgery improves OS in NSCLC with pleural dissemination Surgery is contraindicated in this population, but may benefit select patients.
-
Meta-analysis: exercise tied to lower lung cancer risk in smokers Analysis included 20 studies with >2.9 million participants.
-
Lung cancer: 5-year survival rises over 4 decades, remains low SEER analysis of >1.1 million patients.
-
Research has shown that dacomitinib significantly improves progression-free survival over gefitinib in EGFR-mutation-positive NSCLC.
-
Intervention narrows racial gaps in NSCLC treatment Pragmatic intervention leads to improved treatment rates for all.
-
NSCLC: PD-1 inhibitors safe, effective in ANA+ patients Immune-related AEs did not differ between patients with or without ANA
-
Small-size NSCLC: LNR boosts OS with wedge resection LN resection offered no OS benefit with segmentectomy for tumors 2 cm or smaller.
-
More than 80% of smokers unaware of CT-based lung cancer screens Survey reveals lack of knowledge as the greatest barrier to screening.
-
The rise in pronounced in women from lower socioeconomic groups.
-
Lung cancer: 14% develop chronic opioid use postresection Risk factors include thoracotomy and adjuvant therapy.
-
Mindful breathing reduces dyspnea in lung cancer, COPD, asthma Adding a 20-minute session to standard care shows benefit.
-
ADC: 16.2% of patients have brain metastasis at diagnosis Brain metastases found in 3% of those with stage I disease.